Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate

By sjmartinez • November 29, 2022

Yager J, Brooks KM, Brothers J, Mulligan K, Landovitz RJ, Reirden D, Malhotra M, Glenny C, Harding P, Powell T, Anderson PL, Hosek S. Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. AIDS Res Hum Retroviruses. 2022 Aug 9. doi: 10.1089/AID.2022.0044. Epub ahead of print. PMID: 35815468.

Tags: Estradiol, GAHT, Infectious Diseases, PrEP, Publications, testosterone, transgender men, Transgender women

Related Posts

Lessons learned from COVID-19 to overcome challenges in conducting outpatient clinical trials to find safe and effective therapeutics for the next infectious pandemic

Oh MA, Currier J, Khan A, Mylonakis E, Newell M, Ignacio RB, Jilg N, Safdar B, Merck LH, Smith DM. Lessons learned from COVID-19 to[...]

ACTIV trials: cross-trial lessons learned for master protocol implementation

Keshtkar-Jahromi M, Adam SJ, Brar I, Chung LK, Currier JS, Daar ES, Davey VJ, Denning ET, Gelijns AC, Higgs ES, Jagannathan P, Javan AC, Jensen[...]

Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative

Wohl DA, Adam SJ, Gibbs KW, Moskowitz AL, Ortel TL, Singh U, Jilg N, Evering TH, Fischer WA 2nd, Taiwo BO, Daar ES, Lindsell CJ,[...]